Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps.
Expert Opin Biol Ther
; 24(6): 491-502, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38900023
ABSTRACT
INTRODUCTION:
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent inflammatory condition with heterogenous underlying endotypes, the most common being type 2 mediated inflammation. Several biologics have been developed to target specific pro-inflammatory cytokines and their receptors with proven efficacy in both quantitative and qualitative outcomes in patients with severe uncontrolled disease. However, there is an ongoing debate on the role of biologics relative to conventional therapies for CRSwNP and their efficacy in patient subgroups with non-polyp type 2 disease. AREAS COVERED This review examines the evidence on the efficacy and safety of biologics in CRSwNP, recommendations for their use, and discusses the broader economic factors influencing their application in clinical practice. EXPERT OPINION Emerging real-life data demonstrating the variable efficacy of the available biologics for patients with CRSwNP, coupled with the high cost compared to conventional therapies such as surgery, renders biologics to be considered as an add-on therapy in the majority of cases. However, ongoing research into increasing biologic dose intervals and novel therapies targeting alternative pathways may offer a more cost-effective and sustainable option in future.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Nasal Polyps
/
Rhinosinusitis
Limits:
Humans
Language:
En
Journal:
Expert Opin Biol Ther
Journal subject:
BIOLOGIA
/
TERAPEUTICA
Year:
2024
Document type:
Article
Affiliation country:
United kingdom
Country of publication:
United kingdom